Covid-19: Early results from Moderna vaccine look promising

Health-facts: vaccine covid19

The US biotechnology company Moderna, in partnership with the National Institutes of Health (NIH), is developing a vaccine against the coronavirus, which has been shown to induce immune responses in all volunteers who received it in phase 1 of the study.

Published Tuesday in the New England Journal of Medicine, these first results, showed that the vaccine triggered an immune response with mild side effects – fatigue, chills, headache, muscle pain, pain at the injection site – becoming the first American vaccine candidate to publish his results in a medical journal.

The vaccine is slated to begin a large Phase 3 trial later this month, the final stage of testing before regulators give the go-ahead to market the vaccine.

Moderna said in a statement on Tuesday that, if all goes well in future studies, “society remains on track to be able to deliver around 500 million doses a year, and by 2021, possibly up to one billion doses per year ”.